HR 1796 Re-checks Congress.gov for new actions and updates the bill's status, and fills in any sponsors, committees, or related bills that are missing. It does not re-pull sponsors/cosponsors/committees/related — those rarely change — and it skips all work if nothing has changed upstream, so it's cheap to click.
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025
To amend the Public Health Service Act to reauthorize a sickle cell disease prevention and treatment demonstration program.
Summary
This bill reauthorizes and expands the sickle cell disease prevention and treatment demonstration program under the Public Health Service Act. The bill broadens the program's scope to include treatment of sickle cell disease and prevention and treatment of complications of the disease. The bill also expands funding mechanisms to allow the Secretary of Health and Human Services to make grants or enter into contracts or cooperative agreements with eligible entities, in addition to the existing contract authority. Funding is increased from $4,455,000 annually for fiscal years 2019-2023 to $8,205,000 annually for fiscal years 2025-2029. The bill also expresses the sense of Congress that further research should be undertaken to expand understanding and find cures for heritable blood disorders, including sickle cell disease.
AI-generated plain-language summary of the bill text — neutral, and may be imperfect. See the full text below for the exact wording.
Sponsor (1)
- Rep. James, John [R-MI-10] (R-MI)
6 cosponsors
Actions (2)
- Mar 3, 2025 Referred to the House Committee on Energy and Commerce. · house
- Mar 3, 2025 Introduced in House
More bills on these subjects (8)
Other bills that carry the most legislative subjects in common with this one (topical discovery — distinct from the procedural related bills above).
Similar bills (6)
Bills with similar text or summary — includes reintroductions across Congresses. Ranked by semantic similarity of the bill text (computed locally); a neutral discovery aid, not a claim the bills are duplicates.
Text versions (1)
Bills are re-published as they move (Introduced → Reported → Engrossed → Enrolled …). Each stage below is a separate text; pick two to see what changed. Data from Congress.gov.
Full text
IN THE HOUSE OF REPRESENTATIVES
March 3, 2025
Mr. James (for himself, Mr. Veasey, Mr. Carter of Louisiana, Mr. Davis of Illinois, and Mrs. Kiggans of Virginia) introduced the following bill; which was referred to the Committee on Energy and Commerce
A BILL
To amend the Public Health Service Act to reauthorize a sickle cell disease prevention and treatment demonstration program.
Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the “Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025”.
SEC. 2. SICKLE CELL DISEASE TREATMENT PREVENTION AND TREATMENT.
(a) In General.—Section 1106(b) of the Public Health Service Act (42 U.S.C. 300b-5(b)) is amended—
(1) in paragraph (1)(A)(iii), by striking “prevention and treatment of sickle cell disease” and inserting “treatment of sickle cell disease and the prevention and treatment of complications of sickle cell disease”;
(2) in paragraph (2)(D), by striking “prevention and treatment of sickle cell disease” and inserting “treatment of sickle cell disease and the prevention and treatment of complications of sickle cell disease”;
(3) in paragraph (3)—
(A) in subparagraph (A), by striking “enter into a contract with” and inserting “make a grant to, or enter into a contract or cooperative agreement with,”; and
(B) in subparagraph (B), in each of clauses (ii) and (iii), by striking “prevention and treatment of sickle cell disease” and inserting “treatment of sickle cell disease and the prevention and treatment of complications of sickle cell disease”; and
(4) in paragraph (6), by striking “$4,455,000 for each of fiscal years 2019 through 2023” and inserting “$8,205,000 for each of fiscal years 2025 through 2029”.
(b) Sense of Congress.—It is the sense of Congress that further research should be undertaken to expand the understanding of the causes of, and to find cures for, heritable blood disorders, including sickle cell disease. <all>
Comments